Mon.Jul 01, 2024

article thumbnail

Bird flu snapshot: A pathologist sees familiar echoes in U.S. response to the outbreak

STAT

Bird flu snapshot: This is the latest installment in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates you can also subscribe to STAT’s Morning Rounds newsletter. When pathologist Thijs Kuiken looks at what’s happening in the U.S. response to the H5N1 bird flu outbreak in dairy cows, he’s reminded of a difficult period in the Netherlands, where he lives, back in the late aughts.

364
364
article thumbnail

The IRA will lower U.S. drug spending, CMS finds — but not for awhile

PharmaVoice

As the first 10 drugs undergo price negotiations with the U.S. government, the latest spending projections reveal soon-to-be-implemented price caps will have an impact by 2027.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Ascension is racing to unload hospitals as execs work to stem losses

STAT

For 15 years, a formidable CEO-CFO duo often called “the two Tonys” ushered their St. Louis-based health system through a period of explosive growth, adding hospital after hospital until it became one of the country’s biggest health systems. The year after former CEO Anthony Tersigni and former finance chief Anthony Speranzo stepped down, their sprawling empire of roughly 140 hospitals underwent the ultimate stress test: the Covid-19 pandemic.

Hospitals 360
article thumbnail

Protein power: a biotech mining viruses to fight disease

PharmaVoice

Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.

147
147
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Opinion: Psychiatrists aren’t fulfilling the social contract that subsidized their training

STAT

There has been much handwringing about how difficult it is for Americans with mental health issues to see a psychiatrist. Failures in the health insurance market are often blamed for the problem. As a new class of psychiatry residents begins work in hospitals across the country this week, I see an additional cause: the lack of commitment to honor the subsidies that made it possible for psychiatrists to enter the profession.

Hospitals 350
article thumbnail

10 clinical trials to watch in the second half of 2024

BioPharma Dive

Study results are expected for a pair of closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.

136
136

More Trending

article thumbnail

Eisai and Bristol Myers cancel cancer ADC deal

BioPharma Dive

The Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.

118
118
article thumbnail

STAT+: Novel amputation procedure makes walking with a prosthetic leg feel more seamless

STAT

A novel surgical technique could dramatically improve walking for people with below-the-knee amputations and help them better control their prosthetics. A study published Monday in Nature Medicine showed that trial participants who received the procedure could walk faster, were more stable on uneven terrain, and had an increased spatial awareness, or proprioception, in their residual limb.

322
322
article thumbnail

AstraZeneca files rival to Pemgarda for COVID PrEP

pharmaphorum

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).The drugmaker said this morning that an application for sipavibart (AZD3152) has been accepted for review by the EMA as PrEP for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.

Vaccines 116
article thumbnail

STAT+: After months of warnings, FTC opens investigation into Teva over ‘improper’ patents

STAT

The Federal Trade Commission is formally investigating Teva Pharmaceuticals after the company refused to remove approximately two dozen patents for asthma and COPD inhalers from a key federal registry. The agency sent a civil investigative demand requiring Teva to provide information related to the patents listed in the so-called Orange Book, which is maintained by the Food and Drug Administration.

295
295
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Is the UK’s healthcare spending drop sustainable?

pharmaphorum

Explore the reasons behind the drop in the UK's healthcare spending and analyse whether this trend is sustainable for the NHS in the long term. Learn about the potential impacts and future implications.

116
116
article thumbnail

Opinion: Medicare should wait on approving coverage for new obesity drugs

STAT

My dad, Randy, a 72-year-old retired sales manager, started to gain weight after grad school, and it didn’t let up until he was middle-aged. He’s now living with high blood pressure and high cholesterol. His cardiologist has told him, “You know, if you lost 15 pounds, you could get off your blood pressure medicine.

295
295
article thumbnail

UK’s antibiotic subscription funding model – a route to market sustainability?

Pharmaceutical Technology

On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.

119
119
article thumbnail

STAT+: Pharmalittle: We’re reading about indicted drug wholesalers, a gene therapy rejection, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the familiar routine of online meetings, calls, and deadlines has predictably returned. But you know, the world — such as it is — continues to spin. So what can you do but try to give it a nudge in a better direction.

262
262
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

ASCO 2024: Emphasising the art and science behind enhanced cancer care

pharmaphorum

ASCO 2024 conference highlights the latest advancements in oncology, emphasising the art and science behind enhanced cancer care. Stay updated on the latest research, treatments, and innovations in the field of oncology.

118
118
article thumbnail

CHMP meeting highlights – June 2024

European Pharmaceutical Review

At its recent June meeting, the EMA’s human medicines committee (CHMP) recommended 10 medicines for approval. Recommendations for regulatory approval The committee saw a need to give a marketing authorisation to Balversa (erdafitinib) as a treatment for adults with unresectable or metastatic urothelial carcinoma. In its meeting, the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions.

article thumbnail

Alembic Pharma announces USFDA Tentative Approval for Bosutinib Tablets, 100 mg and 500 mg

Express Pharma

Alembic Pharmaceuticals (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bosutinib Tablets, 100 mg and 500 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Bosulif Tablets, 100 mg and 500 mg, of PF Prism C.V.

111
111
article thumbnail

Why informed patient consent is vital for successful clinical trials

pharmaphorum

Informed patient consent is crucial for the success of clinical trials. Learn about the importance of consent in clinical trials and how it impacts the outcomes.

119
119
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Navigating investment trends in dietary supplement markets

Express Pharma

Season 2 of the Express Pharma – Nutrify Today Boardroom series presents key dialogues from the Nutrify C Suite Sumflex 2024, held over June 6-7, 2024. Transitioning from a latent player a decade ago to a leading market for nutraceutical ingredients and finished products, India is now attracting significant attention from innovators and investors worldwide.

105
105
article thumbnail

ICL granted £150,000 to explore link between breast cancer and breastfeeding

Pharma Times

Breast cancer is the most common cancer in the UK, accounting for 15% of all cancers

134
134
article thumbnail

OPPI urges government to boost R&D and innovation in pharma sector ahead of Union Budget

Express Pharma

In anticipation of the upcoming Union budget, the Organisation of Pharmaceutical Producers of India (OPPI) has voiced its expectations and recommendations for the healthcare and pharma sector. Anil Matai, Director General of OPPI, expressed optimism about the government’s ongoing efforts to enhance quality healthcare and the continuous reforms aimed at bolstering innovation and streamlining regulatory processes.

article thumbnail

Veeva R&D and Quality 2024: Chris Moore

pharmaphorum

An interview with Chris Moore about Veeva R&D and Quality, looking ahead to 2024. Explore insights and predictions for the industry from this expert perspective.

113
113
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Signet Therapeutics announces IND approval by the FDA for world’s first targeted therapy for DGC

Express Pharma

Signet Therapeutics, a biotech company using organoid disease models and AI to advance targeted cancer therapy, today announced that the FDA has granted its IND application for sigx1094 as a potential treatment for diffuse gastric cancer (DGC). According to the statement, sigx1094 is reportedly the first targeted drug candidate for DGC, a disease currently lacking effective treatments.

article thumbnail

Lilly builds in radiopharma with $140m Radionetics deal

pharmaphorum

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outright for $1 billion.Radionetics is working on small-molecule drugs that target G protein-coupled receptors (GPCRs), a fertile source of drug targets for the pharma industry and the target of around a third of all marketed drugs but according to the company is a “largely unexplored” class for radiopharma.

article thumbnail

Eli Lilly inks another radiopharma deal, gaining option to buy startup

BioPharma Dive

Under an arrangement with Radionetics, Lilly will have rights to acquire the San Diego biotechnology company for $1 billion.

111
111
article thumbnail

University of Liverpool launches new biotech spin-out company Galytx

Pharma Times

The biotech company will develop novel therapeutic drugs for the treatment of fatal diseases

122
122
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

World Pharma News

AstraZeneca's Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. Sipavibart is an investigational long-acting antibody designed to provide COVID-19 protection for immunocompromised patients who often do not respond adequately to vaccination alone and remain at high risk of serious outcomes from COVID-19.

article thumbnail

France agrees to fund experimental glioblastoma therapy

pharmaphorum

France's HAS agrees to fund treatment with Carthera's ultrasound device for French subjects enrolled in a glioblastoma trial.

116
116
article thumbnail

How AI is impacting ideation to commercialization in nutraceuticals

Express Pharma

Season 2 of the Express Pharma – Nutrify Today Boardroom series presents key dialogues from the Nutrify C Suite Sumflex 2024, held over June 6-7, 2024. The two day Nutrify Today C Suite Sumflex 2024, where over 360 decision-makers from around the globe gathered to explore and discuss the burgeoning opportunities within the Indian market, mirrored the World Economic Forum on a micro-scale, tailored specifically for the nutraceutical industry.

95
article thumbnail

Pharmacies will revert to old systems if GPs switch off Pharmacy First Update Record

The Pharmacist

Pharmacies will have to revert to using old systems or even paper-based solutions if GPs switch off the Pharmacy First Update Record as advised by the British Medical Association (BMA), sector leaders have warned. As reported earlier today, the BMA urged GPs on Friday to urgently switch off Pharmacy First Update Record, warning the service could […] The post Pharmacies will revert to old systems if GPs switch off Pharmacy First Update Record appeared first on The Pharmacist.

83
article thumbnail

Navigating investment trends in dietary supplement markets

Express Pharma

Season 2 of the Express Pharma – Nutrify Today Boardroom series presents key dialogues from the Nutrify C Suite Sumflex 2024, held over June 6-7, 2024. Transitioning from a latent player a decade ago to a leading market for nutraceutical ingredients and finished products, India is now attracting significant attention from innovators and investors worldwide.

94